(P038) Leukoencephalopathy Following Stereotactic Radiosurgery for Brain Metastases

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Our results establish that WBRT + SRS produces leukoencephalopathy at a much higher rate than SRS alone. Surprisingly, an SRS integral dose of over only 3 J predicts for leukoencephalopathy in patients treated with SRS alone. Our data define a dosimetric threshold at which radiation-induced leukoencephalopathy is likely to occur following SRS. As the survival of patients with CNS metastases increases and as the neurotoxicity of chemotherapeutic and targeted agents becomes established, the threshold of 3 J may influence the therapeutic management of patients with multiple brain metastases.

Daniel M. Trifiletti, MD, Cheng-Chia Lee, MD, David Schlesinger, PhD, Jason P. Sheehan, MD, PhD, James M. Larner, MD;University of Virginia;National Yang-Ming University

PURPOSE/OBJECTIVE: The use of stereotactic radiosurgery (SRS) in the treatment of brain metastases has increased dramatically over the last decade in order to avoid the neurocognitive dysfunction that is induced by whole-brain radiotherapy (WBRT). Technical improvements in SRS delivery have greatly enhanced the SRS workflow and allowed for the treatment of numerous intracranial metastases in a single session. It is now common practice to treat up to 5–10 lesions with SRS in a single session, followed by subsequent SRS sessions based on surveillance imaging; however, the cumulative neurocognitive effect of numerous SRS sessions remains unknown. As leukoencephalopathy is a sensitive marker for radiation-induced central nervous system (CNS) damage, we investigated the dosimetric thresholds for SRS-induced leukoencephalopathy in patients treated with SRS alone, as well as SRS in combination with WBRT.

MATERIALS AND METHODS: All patients treated at our institution with at least two sessions of SRS for brain metastases between 2007 and 2013 were reviewed. Pre- and post-SRS fluid-attenuated inversion recovery and T1- and T2-weighted MRI sequences were reviewed and graded for white matter changes associated with radiation leukoencephalopathy using a previously validated scale. Patient characteristics and SRS dosimetric parameters were reviewed for factors that contributed to radiographic leukoencephalopathy using Cox proportional hazards modeling.

RESULTS: A total of 103 patients meeting the inclusion criteria were identified. The overall incidence of leukoencephalopathy was 53% at 3 years, and four factors predicted for radiation-induced leukoencephalopathy: the use of WBRT (P = .001), SRS integral cranial dose of > 3 J (P = .026), total number of tumors (P = .001), and total tumor volume (P = .009). The volumes receiving 8 Gy (V8), V10, V12, and V15 were not predictive.

CONCLUSIONS: Our results establish that WBRT + SRS produces leukoencephalopathy at a much higher rate than SRS alone. Surprisingly, an SRS integral dose of over only 3 J predicts for leukoencephalopathy in patients treated with SRS alone. Our data define a dosimetric threshold at which radiation-induced leukoencephalopathy is likely to occur following SRS. As the survival of patients with CNS metastases increases and as the neurotoxicity of chemotherapeutic and targeted agents becomes established, the threshold of 3 J may influence the therapeutic management of patients with multiple brain metastases.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content